Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 13.16 is 259% above its 5-year average of -8.28, near the high end of its 5-year range (-11.13–13.16).
338.97% above its 12-month average of -5.51.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 3.73.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T11:05:27.037Z. Historical observations retain their original dates. Historical series through 2026-10-05.
EARNINGS PER SHARE (EPS)
13.16
EARNINGS PER SHARE (EPS) AVG TTM
-5.51
EARNINGS PER SHARE (EPS) AVG 3Y
-7.89
EARNINGS PER SHARE (EPS) AVG 5Y
-8.28
EARNINGS PER SHARE (EPS) AVG 10Y
-6.11
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+338.97%
CURRENT VS 3Y AVG
+266.70%
CURRENT VS 5Y AVG
+259.00%
CURRENT VS 10Y AVG
+315.44%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Ascendis Pharma A/S
Market Cap
$14.16B
Earnings Per Share (EPS)
13.16
TTM Avg
-5.51
3Y Avg
-7.89
5Y Avg
-8.28
Market Cap
$14.64B
Earnings Per Share (EPS)
-1.44
TTM Avg
-3.00
3Y Avg
-2.43
5Y Avg
-2.16
Market Cap
$14.79B
Earnings Per Share (EPS)
3.19
TTM Avg
2.34
3Y Avg
1.78
5Y Avg
1.33
Market Cap
$14.97B
Earnings Per Share (EPS)
-4.85
TTM Avg
-1.35
3Y Avg
4.03
5Y Avg
5.21
Market Cap
$13.19B
Earnings Per Share (EPS)
0.42
TTM Avg
1.15
3Y Avg
1.07
5Y Avg
1.03
Market Cap
$15.24B
Earnings Per Share (EPS)
8.19
TTM Avg
5.85
3Y Avg
6.82
5Y Avg
7.06
Market Cap
$12.95B
Earnings Per Share (EPS)
-3.58
TTM Avg
-3.33
3Y Avg
-3.49
5Y Avg
-3.66
Market Cap
$12.89B
Earnings Per Share (EPS)
4.26
TTM Avg
6.26
3Y Avg
6.54
5Y Avg
5.79
Market Cap
$12.52B
Earnings Per Share (EPS)
-2.04
TTM Avg
-1.51
3Y Avg
-0.65
5Y Avg
0.36
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ascendis Pharma A/S (ASND) | $14.16B | 13.16 | -5.51 | -7.89 | -8.28 |
| Tempus AI, Inc. (TEM)vs › | $14.64B | -1.44 | -3.00 | -2.43 | -2.16 |
| Exelixis, Inc. (EXEL)vs › | $14.79B | 3.19 | 2.34 | 1.78 | 1.33 |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.97B | -4.85 | -1.35 | 4.03 | 5.21 |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 0.42 | 1.15 | 1.07 | 1.03 |
| Solventum Corporation (SOLV)vs › | $15.24B | 8.19 | 5.85 | 6.82 | 7.06 |
| BridgeBio Pharma, Inc. (BBIO)vs › | $12.95B | -3.58 | -3.33 | -3.49 | -3.66 |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 4.26 | 6.26 | 6.54 | 5.79 |
| Baxter International Inc. (BAX)vs › | $12.52B | -2.04 | -1.51 | -0.65 | 0.36 |
| Penumbra, Inc. (PEN)vs › | $12.49B | 4.07 | 2.47 | 1.81 | 1.14 |
Trailing EPS (TTM)
$13.16
Forward EPS (Est.)
N/A
P/E Ratio
17.3
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -4.25 |
| 2024-12-31 | -6.76 |
| 2023-12-31 | -9.44 |
| 2022-12-31 | -11.13 |
| 2021-12-31 | -7.97 |
| 2020-12-31 | -10.11 |
| 2019-12-31 | -5.26 |
| 2018-12-31 | -3.63 |
| 2017-12-31 | -4.42 |
| 2016-12-31 | -2.71 |
| 2015-12-31 | -1.51 |
| 2014-12-31 | -0.69 |
| 2013-12-31 | 0.52 |
| 2012-12-31 | 0.16 |
